These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 22881992

  • 1. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
    Patel DK, Mashon RS, Patel S, Das BS, Purohit P, Bishwal SC.
    Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992
    [Abstract] [Full Text] [Related]

  • 2. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [Abstract] [Full Text] [Related]

  • 3. The effect of hydroxyurea on compound heterozygotes for sickle cell-hemoglobin D-Punjab--a single centre experience in eastern India.
    Patel S, Purohit P, Mashon RS, Dehury S, Meher S, Sahoo S, Dash SS, Das K, Das P, Patel DK.
    Pediatr Blood Cancer; 2014 Aug; 61(8):1341-6. PubMed ID: 24616059
    [Abstract] [Full Text] [Related]

  • 4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hydroxyurea in children: present and future.
    Vichinsky EP.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.
    Youssry I, Abdel-Salam A, Ismail R, Bou-Fakhredin R, Mohamed Samy R, Ezz El-Deen F, Taher AT.
    Hemoglobin; 2017 Jul; 41(4-6):267-273. PubMed ID: 29251012
    [Abstract] [Full Text] [Related]

  • 10. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Jul; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [Abstract] [Full Text] [Related]

  • 12. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [Abstract] [Full Text] [Related]

  • 13. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.
    Blood; 1999 Sep 01; 94(5):1550-4. PubMed ID: 10477679
    [Abstract] [Full Text] [Related]

  • 14. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW, Kennedy LD.
    Ann Pharmacother; 1997 Nov 01; 31(11):1393-6. PubMed ID: 9391697
    [Abstract] [Full Text] [Related]

  • 15. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH, Al-Dabbous IA.
    Saudi Med J; 2002 Mar 01; 23(3):277-81. PubMed ID: 11938415
    [Abstract] [Full Text] [Related]

  • 16. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A, de Bisotti R, Sumoza D, Fairbanks V.
    Am J Hematol; 2002 Nov 01; 71(3):161-5. PubMed ID: 12410569
    [Abstract] [Full Text] [Related]

  • 17. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
    Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.
    Blood; 2010 Mar 25; 115(12):2354-63. PubMed ID: 19903897
    [Abstract] [Full Text] [Related]

  • 18. Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.
    Dehury S, Purohit P, Patel S, Meher S, Kullu BK, Sahoo LK, Patel NK, Mohapatra AK, Das K, Patel DK.
    Pediatr Blood Cancer; 2015 Jun 25; 62(6):1017-23. PubMed ID: 25546091
    [Abstract] [Full Text] [Related]

  • 19. [Effect of hydroxyurea on hemoglobin S].
    Torres AF, Eberle SE, Sciuccati G, Bonduel M.
    Medicina (B Aires); 2003 Jun 25; 63(2):140-2. PubMed ID: 12793083
    [Abstract] [Full Text] [Related]

  • 20. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
    Kattamis A, Lagona E, Orfanou I, Psichou F, Ladis V, Kanavakis E, Metaxotou-Mavrommati A, Kattamis C.
    Pediatr Hematol Oncol; 2004 Jun 25; 21(4):335-42. PubMed ID: 15205096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.